|
Compound class:
Peptide or derivative
Comment: LY3463251 is a synthetic peptide of the growth differentiation factor 15 (GDF15) ligand fused to IgG4-Fc [1]. The Fc moiety extends the agents circulating half-life. LY3463251 acts as a agonist at the GDF15 receptor GFRAL/RET. This action decreases food intake and body weight in animal models, providing proof of concept for this mechanism as a weight-loss approach.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| LY3463251 has advanced to early stage clinical evaluation to determine safety and tolerability in healthy participants. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03764774 | A Study of LY3463251 in Healthy Participants | Phase 1 Interventional | Eli Lilly and Company | ||
